Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


EU approves Abrysvo for respiratory syncytial virus – Pfizer

Written by | 3 Sep 2023 | Pharma News

Pfizer announced that the European Commission (EC) has granted marketing authorization for Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to help protect both infants through maternal immunization and older adults. Abrysvo is indicated for: Passive protection against lower respiratory tract disease (LRTD) caused by RSV in infants from birth through six months of age following maternal immunization during pregnancy, and active immunization of individuals 60 years of age and older for the prevention of LRTD caused by RSV.

This marketing authorization follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states plus Iceland, Liechtenstein, and Norway. Abrysvo is the first licensed vaccine designed and studied explicitly for maternal immunization and now a single dose of the vaccine could be administered in the EU between weeks 24 and 36 of gestation. In addition, Abrysvo has been studied in adults 60 years of age and older. The marketing authorization includes single-dose use in this population as well.

The EU marketing authorization for Abrysvo is based on evidence from two Phase III clinical trials – RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease) and MATISSE (MATernal Immunization Study for Safety and Efficacy).

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.